为探究 UDCA 对肥胖、高血压等慢性疾病的影响，相关研究人员开展关于 UDCA 对人体测量指标、血压和炎症影响的研究，发现其可改善 BMI 和 DBP，但会升高 SBP。该研究为临床治疗提供参考，推荐科研读者阅读。 在当今社会，肥胖、高血压和代谢综合征等慢性疾病 ...

对UDCA生化应答不佳患者（非失代偿 ... 也可联合苯扎贝特（400 mg/d）或非诺贝特（200 mg/d）治疗。 肝移植 PBC进展至肝硬化失代偿期（腹腔积液、食管 ...

UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Ursodeoxycholic acid (UDCA) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies of diverse etiologies and has been mainly used as a supportive treatment in ...

Degree of benefit with UDCA is uncertain. Aim: To Look at Mode of diagnosis for CFALD and Effectiveness & safety of UDCA in our unit. Methods: Retrospective review on all patients currently ...